GRAS notifications
Daepyung has received FDA no objections letters regarding two enzyme-modified steviol glycoside products (GRNs 448 and 452) where the subject materials were 100x and 150x sweeter than sucrose respectively, but has also developed technology to convert the more abundant Reb A into the more sought after minor glycoside Reb D.